SALIVARY GLAND CANCER
Clinical trials for SALIVARY GLAND CANCER explained in plain language.
Never miss a new study
Get alerted when new SALIVARY GLAND CANCER trials appear
Sign up with your email to follow new studies for SALIVARY GLAND CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug hope for rare salivary gland cancer
Disease control OngoingThis phase 2 trial tests whether amivantamab can shrink tumors or slow disease in 21 people with recurrent or metastatic adenoid cystic carcinoma, a rare salivary gland cancer. Participants receive weekly or biweekly infusions of the drug. The main goal is to see how many patient…
Matched conditions: SALIVARY GLAND CANCER
Phase: PHASE2 • Sponsor: Trisha Wise-Draper • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Immunotherapy-Chemo combo takes on stubborn thyroid and salivary tumors
Disease control OngoingThis phase 2 trial is testing whether combining the immunotherapy drug pembrolizumab (Keytruda) with the chemotherapy drug docetaxel can shrink or control advanced thyroid and salivary gland cancers that are not responding to standard treatments. About 46 participants will receiv…
Matched conditions: SALIVARY GLAND CANCER
Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug shows promise against rare salivary gland cancer
Disease control OngoingThis study tests a new drug called APG-115, alone or with chemotherapy, in people with a certain type of salivary gland cancer that has a normal p53 gene. The goal is to see if the drug can shrink tumors and to find the best dose with acceptable side effects. About 41 adults with…
Matched conditions: SALIVARY GLAND CANCER
Phase: PHASE1, PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New drug combo shows promise for rare salivary gland cancers
Disease control OngoingThis study tests whether two drugs, lenvatinib and pembrolizumab, can shrink or slow the growth of advanced salivary gland cancers, including adenoid cystic carcinoma, that have come back or spread. About 64 participants will receive the combination therapy. The goal is to see ho…
Matched conditions: SALIVARY GLAND CANCER
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Keytruda takes on 15 advanced cancers in major trial
Disease control OngoingThis phase 2 trial tests the immunotherapy drug pembrolizumab (Keytruda) in people with 15 types of advanced solid tumors that have worsened after standard treatments. About 1,600 participants receive the drug to see if their tumors shrink or stop growing. The study also looks fo…
Matched conditions: SALIVARY GLAND CANCER
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Proton beam vs. standard radiation: which is gentler on head and neck cancer patients?
Symptom relief OngoingThis study compares proton beam radiation to standard photon radiation (IMRT) for people with head and neck cancer. The goal is to see if proton therapy causes fewer side effects, like painful mouth sores, by exposing less healthy tissue to radiation. About 108 adults with certai…
Matched conditions: SALIVARY GLAND CANCER
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC